-
Bavdegalutamide is an
experimental proteolysis targeting chimera that
functions as a
androgen receptor degrader. It is
being developed to
treat metastatic...
- in 2013–14. In 2019,
Arvinas put two
PROTACs into
clinical trials:
bavdegalutamide (ARV-110), an
androgen receptor degrader, and
vepdegestrant (ARV-471)...
-
degraders targeting the
androgen receptor have been
tested in the clinic:
Bavdegalutamide (ARV-110):
Developed by Arvinas, this
PROTAC is
currently in phase...
- AA560
Antarlides Arabilin Apalutamide Atraric acid AZD-3514
Bakuchiol Bavdegalutamide BAY-1024767
Bicalutamide Bisphenols (e.g., BADGE, BFDGE, bisphenol...
- AA560
Antarlides Arabilin Apalutamide Atraric acid AZD-3514
Bakuchiol Bavdegalutamide BAY-1024767
Bicalutamide Bisphenols (e.g., BADGE, BFDGE, bisphenol...
- AA560
Antarlides Arabilin Apalutamide Atraric acid AZD-3514
Bakuchiol Bavdegalutamide BAY-1024767
Bicalutamide Bisphenols (e.g., BADGE, BFDGE, bisphenol...
- AA560
Antarlides Arabilin Apalutamide Atraric acid AZD-3514
Bakuchiol Bavdegalutamide BAY-1024767
Bicalutamide Bisphenols (e.g., BADGE, BFDGE, bisphenol...
- AA560
Antarlides Arabilin Apalutamide Atraric acid AZD-3514
Bakuchiol Bavdegalutamide BAY-1024767
Bicalutamide Bisphenols (e.g., BADGE, BFDGE, bisphenol...
- AA560
Antarlides Arabilin Apalutamide Atraric acid AZD-3514
Bakuchiol Bavdegalutamide BAY-1024767
Bicalutamide Bisphenols (e.g., BADGE, BFDGE, bisphenol...
- AA560
Antarlides Arabilin Apalutamide Atraric acid AZD-3514
Bakuchiol Bavdegalutamide BAY-1024767
Bicalutamide Bisphenols (e.g., BADGE, BFDGE, bisphenol...
